Antibe Therapeutics, Inc. ( Antibe Therapeutics)

Primary tabs

Antibe Therapeutics's picture

Management

Contact Address

About Antibe Therapeutics, Inc.

Antibe develops safer medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation.

Antibe Therapeutics press release, blog etc

Wed, 11/02/2022 - 03:20 Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary
Tue, 10/11/2022 - 19:49 Antibe Provides Development Update for Otenaproxesul
Tue, 06/14/2022 - 21:13 Antibe Therapeutics Announces Amendment to Warrant Terms
Tue, 05/24/2022 - 20:53 Antibe Therapeutics Appoints New Board Chair and Corporate Vice Chairs
Sun, 05/01/2022 - 22:27 Antibe Therapeutics Announces Strategic Sale of Citagenix Subsidiary
Mon, 04/25/2022 - 01:59 Antibe Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Mon, 02/14/2022 - 03:17 Antibe Therapeutics Reports Q3 2022 Interim Financial and Operating Results
Thu, 10/14/2021 - 04:43 Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline
Wed, 09/08/2021 - 14:07 Antibe Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Thu, 08/19/2021 - 13:22 Antibe Therapeutics Announces Results of 2021 Annual Meeting
Tue, 08/17/2021 - 15:23 Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results
Mon, 08/09/2021 - 16:02 Antibe Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
Tue, 08/03/2021 - 15:32 Antibe Therapeutics Provides Clinical Update for Otenaproxesul
Mon, 06/28/2021 - 13:29 Antibe Therapeutics Reports 2021 Year-End Results and Business Highlights
Fri, 06/25/2021 - 13:43 Antibe Therapeutics Collaborates with Dalriada Drug Discovery to Accelerate Pipeline Expansion
Thu, 06/03/2021 - 13:32 Antibe Therapeutics Announces Close of Amalgamation Transaction to Unify Intellectual Property Ownership
Fri, 05/07/2021 - 14:42 Antibe Therapeutics Announces Agreement to Unify Intellectual Property Ownership
Wed, 04/14/2021 - 14:13 Antibe Therapeutics to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference